EU implements plan to prevent falsified medicines
The European Medicines Agency and the European Commission have published a plan to prevent falsified medicines from entering the market. The regulation introduces two safety features: a unique identifier and an anti-tampering device to be placed on the packaging of most medicines. “The safety features will help protect European citizens ...
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
Article
European Medicines Agency issues data integrity guidance
The pharmaceutical industry faces fresh regulatory pressure around the world over data integrity issues, reports Jaclyn Jaeger, particularly involving clinical trials.
-
ArticleDecision time for compliance as U.K. CCI regime ditches formulaic reporting to engage investors
A new U.K. Consumer Composite Investments regime comes into force on April 6 and will apply to all firms that manufacture or distribute CCI products to retail investors in the U.K. This includes some firms that are not regulated by the Financial Conduct Authority.
-
News BriefEY compliance partner leaves after independence failings prompt regulatory investigation
Four senior partners at Big Four accountancy firm Ernst & Young, including a leader in the firm’s compliance function, have left the company because of spiralling repercussions from a costly compliance failure.